Real-life biomarker response to anti-IL5 and anti-IgE therapies in severe asthma patients
S. Burkill (Singapore, Singapore), C. M. Porsbjerg (Bispebjerg, Denmark), A. Bourdin (Montpellier, France), T. N Tran (Gaithersburg, United States), N. Martin (Gaithersburg, United States), R. Katial (Gaithersburg, United States), P. Barker (Gaithersburg, United States), M. E Wechsler (Denver, United States), J. Maspero (Buenos Aires, Argentina), S. Bosnic-Anticevich (Sydney, Australia), L. Chung (Perth, Australia), G. Katsoulotos (Sydney, Australia), G. C Christoff (Sofia, Bulgaria), T. A Popov (Sofia, Bulgaria), M. Sadatsafavi (Vancouver, Canada), C. A Torres-Duque (Bogotá, Colombia), C. Ulrik (Hvidovre, Denmark), K. Dahl Assing (Aalborg, Denmark), S. Hansen (Copenhagen, Denmark), A. Altraja (Tartu, Estonia), L. A Lehtimaki (Tampere, Finland), N. G Papadopoulos (Athens, Greece), K. Kostikas (Ioannina, Greece), S. Salvi (Pune, India), R. W Costello (Dublin, Ireland), P. Francesca (Rozzano, Italy), T. Iwanaga (Osakasayama, Japan), C. Rhee (Seoul, Republic of Korea), M. Al-Ahmad (Kuwait, Kuwait), D. Larenas-Linnemann (Ciudad de México, Mexico), J. A Fonseca (Porto, Portugal), R. Amaral (Sweden, Sweden), K. Alving (Sweden, Sweden), R. Al-Lehebi (Riyadh, Saudi Arabia), L. Perez De-Llano (Monforte, Cervo, Italy), B. Kirenga (Kampala, Uganda), M. Tsai (Taiwan, Taiwan), B. Mahboub (Sharjah, United Arab Emirates), P. E Pfeffer (London, United Kingdom), W. Henley (Singapore, Singapore), Y. Liu (Brisbane, Australia), J. Lyu (Singapore, Singapore), C. Goh (Singapore, Singapore), T. Uthaman (Singapore, Singapore), D. Price (Singapore, Singapore), J. Townend (Norwich, United Kingdom)
Source: International Congress 2022 – Studies targeting IL-5 pathways in asthma
Session: Studies targeting IL-5 pathways in asthma
Session type: Thematic Poster
Number: 2136
 
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
S. Burkill (Singapore, Singapore), C. M. Porsbjerg (Bispebjerg, Denmark), A. Bourdin (Montpellier, France), T. N Tran (Gaithersburg, United States), N. Martin (Gaithersburg, United States), R. Katial (Gaithersburg, United States), P. Barker (Gaithersburg, United States), M. E Wechsler (Denver, United States), J. Maspero (Buenos Aires, Argentina), S. Bosnic-Anticevich (Sydney, Australia), L. Chung (Perth, Australia), G. Katsoulotos (Sydney, Australia), G. C Christoff (Sofia, Bulgaria), T. A Popov (Sofia, Bulgaria), M. Sadatsafavi (Vancouver, Canada), C. A Torres-Duque (Bogotá, Colombia), C. Ulrik (Hvidovre, Denmark), K. Dahl Assing (Aalborg, Denmark), S. Hansen (Copenhagen, Denmark), A. Altraja (Tartu, Estonia), L. A Lehtimaki (Tampere, Finland), N. G Papadopoulos (Athens, Greece), K. Kostikas (Ioannina, Greece), S. Salvi (Pune, India), R. W Costello (Dublin, Ireland), P. Francesca (Rozzano, Italy), T. Iwanaga (Osakasayama, Japan), C. Rhee (Seoul, Republic of Korea), M. Al-Ahmad (Kuwait, Kuwait), D. Larenas-Linnemann (Ciudad de México, Mexico), J. A Fonseca (Porto, Portugal), R. Amaral (Sweden, Sweden), K. Alving (Sweden, Sweden), R. Al-Lehebi (Riyadh, Saudi Arabia), L. Perez De-Llano (Monforte, Cervo, Italy), B. Kirenga (Kampala, Uganda), M. Tsai (Taiwan, Taiwan), B. Mahboub (Sharjah, United Arab Emirates), P. E Pfeffer (London, United Kingdom), W. Henley (Singapore, Singapore), Y. Liu (Brisbane, Australia), J. Lyu (Singapore, Singapore), C. Goh (Singapore, Singapore), T. Uthaman (Singapore, Singapore), D. Price (Singapore, Singapore), J. Townend (Norwich, United Kingdom). Real-life biomarker response to anti-IL5 and anti-IgE therapies in severe asthma patients. 2136
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|